Market Overview on Acute Ischemic Stroke - Pipeline Review, H2 2016

Acute Ischemic Stroke - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Acute Ischemic Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Complete report available @ Acute Ischemic Stroke - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
- The report assesses Acute Ischemic Stroke therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AB Science SA AstraZeneca Plc Biogen Inc D-Pharm Ltd. Daiichi Sankyo Company, Limited DiaMedica Inc. Digna Biotech, S.L. Glucox Biotech AB Jeil Pharmaceutical Co., Ltd. Lumosa Therapeutics Co., Ltd. Mitsubishi Tanabe Pharma Corporation Pharmicell Co., Ltd. PhytoHealth Corporation Remedy Pharmaceuticals, Inc. Saneron CCEL Therapeutics, Inc. Simcere Pharmaceutical Group Stemedica Cell Technologies, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###